Vertex Pharmaceuticals (NASDAQ:VRTX) is recommended as a low volatility stock with strong growth potential by Bank of America Securities analyst Tazeen Ahmad, citing steady revenue growth in cystic fibrosis treatments like Alyftrek and Trikafta.